Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

Please include copies of all insurance cards and print legibly, using blue or black ink.

This form serves a dual purpose. It allows patients to register for AMICUS ASSIST® and also serves as a prescription for Galafold.

 $\square$  I opt not to enroll in AMICUS ASSIST at this time. I understand that this will not prohibit my receiving therapy with Galafold.

**Step 1:** Complete the following information to register the patient for AMICUS ASSIST.

| This form will also act as a prescription and statement of medical  | necessity for Galafold.   |  |  |  |
|---|---|--|--|--|
| Patient Information (The correct patient information is necessary for to register the patient with AMICUS ASSIST.)  | or timely processing. Complete all fields and provide accurate information  |  |  |  |
| First Name: MI:   | Last Name:  |  |  |  |
| Address 1:  | Address 2:  |  |  |  |
| City: State: Zip:   | DOB: Gender: Dale Female  |  |  |  |
| Preferred Phone #: C  | an we leave a message on this phone? 🗆 Yes 🗆 No   |  |  |  |
| Alternate Authorized Contact:   | Phone #:  |  |  |  |
| Relationship to Patient:  |   |  |  |  |
| May an AMICUS ASSIST Case Manager contact the patient by email?   | ☐ Yes ☐ No Email:   |  |  |  |
| Preferred Method of Contact:  | Preferred Time of Contact:  |  |  |  |
| Insurance Information (If available, photocopy the front and back and prescription insurance cards and submit   | of the patient's medical No Insurance   |  |  |  |
| Primary Insurance:  | Secondary Insurance:  |  |  |  |
| Policy Holder:  | ·   |  |  |  |
| Policy ID #:  | Policy ID #:  |  |  |  |
| Group #:  | Group #:  |  |  |  |
| Phone #:  | Phone #:  |  |  |  |
| Prescription Card (Name):   | Phone #:  |  |  |  |
| Group #: ID #:  | Rx Bin #: PCN #:  |  |  |  |
| Prescriber Information (Complete all information in this section as   | s it is essential for the Galafold prescription to be filled.)  |  |  |  |
| First Name:   | Last Name:  |  |  |  |
| Office/Institution:   |   |  |  |  |
| Address:  |   |  |  |  |
| City: State: Zip:   | Phone # Fax #:  |  |  |  |
| Email: NPI #:   | State License #:  |  |  |  |
| Contact Person:   |   |  |  |  |
| Contact Phone # (direct):   | Contact Email:  |  |  |  |
| This section serves as a prescription for Galafold. Include the number of refills necessary to prevent disruptions in product access.  Any changes will require the submission of a new form. Note: this may not serve as a prescription in all states.   |   |  |  |  |
|   | lay not serve as a prescription in all states.  |  |  |  |
| Prescription Information: Galafold* (migalastat) 123 mg/cap NDC #:  ICD-10 Code: E75.21  Dosing Instructions: 123 mg PO (by mouth) every other day for Dispensing Quantity: No. of Refills:   | 71904-100-01 (wallet containing 14 capsules)  |  |  |  |
| ICD-10 Code: E75.21  Dosing Instructions: 123 mg PO (by mouth) every other day for  | of Fabry and that the information provided is accurate to the best of rm or any information contained on this form to the insurer of the rmy office has obtained HIPAA-compliant authorization from the abovey for Amicus to provide services described in the Patient Authorization ontact the patient/caregiver as needed to process this Referral Form.  |  |  |  |
| ICD-10 Code: E75.21 Dosing Instructions: 123 mg PO (by mouth) every other day for Dispensing Quantity:  I certify that the above therapy is medically necessary for the treatment of my knowledge. I appoint AMICUS ASSIST, on my behalf, to provide this for above-named patient or to the dispensing pharmacy. I hereby certify that mentioned patient to disclose the protected health information necessar on page 2 of the Galafold Referral Form. I also allow AMICUS ASSIST to confide the prescriber's signature is required to initiate registration in AMICUS Prescriber's Signature: | of Fabry and that the information provided is accurate to the best of rm or any information contained on this form to the insurer of the rmy office has obtained HIPAA-compliant authorization from the abovey for Amicus to provide services described in the Patient Authorization ontact the patient/caregiver as needed to process this Referral Form.  15 ASSIST and to fill the prescription for Galafold.  Date: |  |  |  |
| ICD-10 Code: E75.21  Dosing Instructions: 123 mg PO (by mouth) every other day for Dispensing Quantity:   | of Fabry and that the information provided is accurate to the best of rm or any information contained on this form to the insurer of the rmy office has obtained HIPAA-compliant authorization from the abovey for Amicus to provide services described in the Patient Authorization ontact the patient/caregiver as needed to process this Referral Form.  15 ASSIST and to fill the prescription for Galafold.  Date: |  |  |  |
| ICD-10 Code: E75.21 Dosing Instructions: 123 mg PO (by mouth) every other day for Dispensing Quantity:  I certify that the above therapy is medically necessary for the treatment of my knowledge. I appoint AMICUS ASSIST, on my behalf, to provide this for above-named patient or to the dispensing pharmacy. I hereby certify that mentioned patient to disclose the protected health information necessar on page 2 of the Galafold Referral Form. I also allow AMICUS ASSIST to confide the prescriber's signature is required to initiate registration in AMICUS Prescriber's Signature: | of Fabry and that the information provided is accurate to the best of rm or any information contained on this form to the insurer of the rmy office has obtained HIPAA-compliant authorization from the abovey for Amicus to provide services described in the Patient Authorization ontact the patient/caregiver as needed to process this Referral Form.  15 ASSIST and to fill the prescription for Galafold.  Date: |  |  |  |

ation,

Instructions: Complete the Patient Authorization on page 2 and the Statement of Medical Necessity on page 3.

Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

Step 2: Obtain patient authorization. Please have patient review and sign authorization below in order to enroll in AMICUS ASSIST®.

## Patient Authorization for Use and Disclosure of Health Information Pursuant to 45 C.F.R. §164.508

By signing this authorization ("Authorization"), I hereby certify and agree to the following:

I am (i) the Patient (identified in Step 1 above) and legally permitted to make decisions about how my health information is used and disclosed or (ii) the parent, legal guardian, or authorized representative of the Patient and legally permitted to make decisions about how the Patient's health information is used and disclosed.

I authorize my physician, identified on page 1 of this Referral Form, and their staff to disclose my health and other personal and protected health information, including but not limited to, the information on this Referral Form and information deemed relevant by my physician that may be considered sensitive or specially protected under state law, to Amicus and its agents and representatives (collectively "Amicus") so that Amicus may use and further disclose my information to healthcare providers, pharmacies, insurance companies, prescription drug plans, and other third-party payers (collectively, "Third Parties") in order to: (1) facilitate the filling of my prescription for and the delivery and administration of Galafold; (2) assist me in obtaining insurance coverage for Galafold; (3) contact me by mail, email, and/or telephone or text message to enroll me in, and administer, programs that provide Galafold support services; (4) contact me via those methods specified in (3) to provide me with free educational information and product materials; (5) conduct quality assurance, surveys, and other internal business activities in connection with Galafold and Galafold support services; and/or (6) address adverse events and product quality complaints.

I authorize my healthcare providers, including my physician identified on page 1 of this Referral Form, and their staff and my pharmacies to disclose my health and other personal and protected health information, including but not limited to the information about me in their possession, to Amicus in order to assist Amicus in accomplishing the purposes described above.

I understand that information disclosed pursuant to this Authorization could be re-disclosed by Recipients. Such re-disclosed information may no longer be protected by federal or state medical privacy laws, including the Health Insurance Portability and Accountability Act or "HIPAA."

I understand that I may refuse to sign this Authorization and such refusal will not affect my ability to receive Galafold, my treatment, payment for treatment, enrollment in a health plan or eligibility for benefits, but it will limit my ability to receive support services for Galafold from Amicus.

This Authorization will expire in 10 years after the date it is signed unless a shorter period is mandated by state law or I revoke or cancel my Authorization by contacting Amicus in writing at:

### **ATTENTION: AMICUS ASSIST**

Amicus Therapeutics 3675 Market Street Philadelphia, PA 19104

If I revoke this Authorization, Amicus will stop using and disclosing my information as soon as possible, but the revocation will not affect prior use or disclosure of my information in reliance on this Authorization.

I understand that the services provided by Amicus that I have agreed to, and that are described in this Authorization, may be reduced or terminated at any time, without prior notice.

I understand that my pharmacy, health insurer(s), or healthcare providers may receive remuneration from Amicus for disclosing pursuant to this Authorization certain personal and medical information related to the AMICUS ASSIST activities conducted on my behalf so that Amicus may administer, assess and improve the quality of services being provided to patients. I also understand that my pharmacy may receive remuneration from Amicus for administering some of the services which are described above.

I am aware that I can review the Amicus Privacy Policy, including information for California residents, by visiting www.amicusrx.com/privacy-policy. I have received a copy of this Authorization.

| Patient's Signature                                | Date |
|--|------|
| Patient's Name (please print)                      |      |
| Patient's Authorized Representative (please print) |      |
| Relationship to Patient                            |      |
| Authorized Representative's Signature              | Date |

The patient's signature is required to release his/her health information to AMICUS ASSIST and to open a dialogue about insurance.



Email forms to: assist@amicusrx.com | Fax completed forms to: 1-833-264-2873

Questions? Call toll-free: 1-833-AMICUS-A (1-833-264-2872)

**Step 3:** Submit the completed form.

| Statement of Medica      | al Necessity – Galafold   |                                   |                           |
|--------------------------|---|-----------------------------------|---------------------------|
| Patient Name/Inform      | nation:   |                                   |                           |
| First Name:              | MI:   | Last Name:                        |                           |
| DOB:                     |   |                                   |                           |
| Drug/Non-Drug Alle       | rgies:  |                                   | □ No known drug allergies |
| Diagnosis:               |   |                                   |                           |
| Fabry Disease ICD-10     | <b>Code:</b> E75.21   |                                   |                           |
| Date of Diagnosis:       |   |                                   |                           |
| Method of Diagnosis      | (check all that apply):   |                                   |                           |
| ☐ Clinical signs         | □ α-Gal A enzyme activity levels  | ☐ Genotype                        |                           |
| □ Other                  |   |                                   |                           |
| Amenable <i>GLA</i> Gene | Variant:  |                                   |                           |
| □Yes □No                 | GLA Gene Variant:   |                                   |                           |
| Clinical Signs and Syn   | nptoms:   |                                   |                           |
| Current/Prior Treatm     | ent Plan:   |                                   |                           |
| Therapy:                 |   | Dose:                             |                           |
| Date Initiated:          | Date Discontinued (in   | f applicable):                    |                           |
| Therapy:                 |   | Dose:                             |                           |
| Date Initiated:          | Date Discontinued (in   | f applicable):                    |                           |
| Other Medications: _     |   |                                   |                           |
|                          |   |                                   |                           |
|                          |   |                                   |                           |
| to the best of my know   | e therapy is medically necessary for the vledge. I appoint AMICUS ASSIST®, on n<br>the above-named patient or to the disp | ny behalf, to provide this form o |                           |
| Prescriber's Name (plea  | ase print):   | D                                 | ate:                      |
| Prescriber's Signature:  |   |                                   |                           |
| State License #          |   |                                   |                           |



### INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (*GLA*) variant based on *in vitro* assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

#### IMPORTANT SAFETY INFORMATION

### **ADVERSE REACTIONS**

The most common adverse drug reactions reported with Galafold (≥10 %) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

### **USE IN SPECIFIC POPULATIONS**

There is insufficient clinical data on Galafold use in pregnant women to inform a drug associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4-AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying Full Prescribing Information, also available at https://www.amicusrx.com/pi/galafold.pdf.



